Showing results (51-60 of 265) with videos related to
Sort By:
Pageof 27
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1995
Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in miceF Innocenti, R Danesi, A Di Paolo, et al.Pharmacological Research|September 1, 1995
Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell linesA di Paolo, G Bocci, F Innocenti, et al.Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer|January 1, 1994
Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicinA Pinna, C Agen, A Di Paolo, et al.Journal of Chemotherapy (Florence, Italy)|January 26, 2006
Idarubicin and idarubicinol effects on breast cancer multicellular spheroidsP Orlandi, C Barbara, G Bocci, et al.Seminars in Oncology|March 4, 2000
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancerA Gennari, S Donati, R Danesi, et al.Cancer|January 15, 1995
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II studyA Falcone, E Pfanner, C Cianci, et al.Naunyn-Schmiedeberg'S Archives of Pharmacology|May 5, 1978
Acetylcholine content of and release from isolated pelviureteral tractM Del TaccaTransplantation Proceedings|April 28, 2004
Prospects for personalized immunosuppression: pharmacologic tools--a reviewM Del TaccaBritish Journal of Cancer|June 1, 1993
Involvement of basic fibroblast growth factor in suramin-induced inhibition of V79/AP4 fibroblast cell proliferationN Bernardini, F Giannessi, F Bianchi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancerS Fogli, R Danesi, F De Braud, et al.Pageof 27